Drug
Epaminurad clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 1
- first study started
- 2023
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
4 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 1
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses epaminurad is read from its arms, and is right about nine times in ten.
Testing it · 4
- To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy VolunteersCompletedPhase 1JW PharmaceuticalNCT07374406Written as Epaminurad 9 mg (JW Pharmaceutical)
- A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout PatientsCompletedPhase 3JW PharmaceuticalNCT05815901Written as Epaminurad 6 mg
- PK,PD and DDI of Epaminurad and C2406 in Healthy VolunteersCompletedPhase 1JW PharmaceuticalNCT06665425Written as Epaminurad 9 mg
- PK,PD and DDI of Epaminurad and Naproxen in Healthy VolunteersCompletedPhase 1JW PharmaceuticalNCT06435442Written as Epaminurad, Naproxen
Codes
What other systems call epaminurad · ClinicalTrials.gg INT014246
- UNII (FDA) 0YP1ME85GHEPAMINURADOne source FDA
- NCI Thesaurus C166441EpaminuradOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0YP1ME85GH | EPAMINURAD | One source FDA |
| NCI Thesaurus | C166441 | Epaminurad | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.